Occlusal splint or botulinum toxin-a for jaw muscle pain treatment in probable sleep bruxism: A randomized controlled trial

被引:0
|
作者
Chisini, Luiz Alexandre [1 ]
Pires, Ana Luiza Cardoso [1 ]
Poletto-Neto, Victorio [1 ]
Damian, Melissa Feres [1 ]
Luz, Murilo Souza [2 ]
Loomans, Bas [3 ]
Pereira-Cenci, Tatiana [3 ]
机构
[1] Univ Fed Pelotas, Grad Program Dent, Pelotas, Brazil
[2] Atitus Educ, Dept Dent, Porto Alegre, Brazil
[3] Radboud Univ Nijmegen, Med Ctr Nijmegen, Dept Dent, Nijmegen, Netherlands
关键词
Facial pain; Pain management; Chronic pain; Clinical Trial; TEMPOROMANDIBULAR-JOINT DISORDERS; MYOFASCIAL PAIN; ASSOCIATION; INJECTIONS; THERAPY; NETWORK;
D O I
10.1016/j.jdent.2024.105439
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objectives: To conduct an equivalency randomized controlled trial comparing occlusal splint (OS) and botulinum toxin-A (BTX-A) on jaw muscle pain in probable sleep bruxism. Methods: Sixty patients (>= 18 years, probable sleep bruxism, and jaw muscle pain) were randomly allocated into groups. The primary outcome was the reduction of jaw muscle pain, assessed using the Graded Chronic Pain Scale (GCPS, v2.0). Secondary outcomes included: parameters of jaw opening and mandibular mobility; distribution of muscle pain; Jaw Functional Limitation Scale-20 (JFLS-20), Oral Behaviors Checklist (OBC); and Oral Health Impact Profile-14 (OHIP-14). Only the evaluator was blinded. Multilevel mixed-effects regression models were used. Results: Fifty-nine patients (30 received OS and 29 BTX-A) were analyzed at baseline, 3 and 6 months follow-up. One patient dropped out after receiving the intervention. No differences between the interventions were observed concerning the GCPS (p = 0.627), although a significant reduction was observed at 3 (OR=13.26, 95% CI[6.61-26.59]) and 6 months (OR=12.36, 95%CI[4.93-30.98]), regardless of the treatment. BTX-A showed a lower score reduction on JFLS-20 than OS (OR=0.29, 95%CI[0.11-0.82]). BTX-A presented inferior results for the parameters: opening without pain(p = 0.045), unassisted maximum opening(p = 0.024), assisted maximum opening(p = 0.041), and protrusion(p = 0.016). An improvement in OHIP-14 scores was observed at 3 (IRR=1.08, CI95%[1.02-1.14]) and 6 months (IRR=1.10, CI95%[1.04-1.16]), regardless of the intervention. BTX-A participants(n = 23;79,3%) reported mild discomfort during chewing. Conclusion: OS and BTX-A can effectively decrease the GCPS scores, improve OHRQoL, and enhance functional outcomes in sleep bruxist patients with jaw muscle pain. OS demonstrated slight advantages in specific parameters. Clinical Significance: Both occlusal splints and botulinum toxin-A effectively reduce jaw muscle pain in bruxist patients, improving quality of life and mandibular function. Clinically, occlusal splints may offer additional benefits in specific functional parameters. (NCT03456154)
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Repeat botulinum toxin-A injections in the upper limb of children with hemiplegia: a randomized controlled trial
    Olesch, Christine A.
    Greaves, Susan
    Imms, Christine
    Reid, Susan M.
    Graham, H. Kerr
    DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2010, 52 (01): : 79 - 86
  • [22] The Association of Awake and Asleep Bruxism With Muscle Pain in Patients Undergoing Botulinum Toxin Treatment
    Orlova, Olga
    Buldyaeva, Olesya
    Artemenko, Ada
    Konovalova, Zagidat
    Yakovleva, Polina
    Krasavina, Diana
    Mingazova, Leniza
    Soykher, Marina
    TOXICON, 2024, 237 : 67 - 67
  • [23] Pressure Algometry Evaluation of Two Occlusal Splint Designs in Bruxism Management-Randomized, Controlled Clinical Trial
    Dalewski, Bartosz
    Kaminska, Agata
    Kiczmer, Pawel
    Wegrzyn, Krzysztof
    Palka, Lukasz
    Janda, Katarzyna
    Sobolewska, Ewa
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (11)
  • [24] Randomized controlled trial of botulinum toxin A for chronic myogenous orofacial pain
    Nixdorf, DR
    Heo, G
    Major, PW
    PAIN, 2002, 99 (03) : 465 - 473
  • [25] A First Clinical Trial on Botulinum Toxin-A for Chronic Muscle-Related Pain in Cerebral Palsy
    Jacobson, Dan
    Lowing, Kristina
    Kullander, Kjell
    Rydh, Britt-Marie
    Tedroff, Kristina
    FRONTIERS IN NEUROLOGY, 2021, 12
  • [26] Botulinum Toxin A as a Treatment for Provoked Vestibulodynia: A Randomized Controlled Trial
    Chescheir, Nancy C.
    OBSTETRICS AND GYNECOLOGY, 2020, 136 (03): : 629 - 629
  • [27] BOTULINUM TOXIN-A FOR REFRACTORY DETRUSOR OVERACTIVITY IN WOMEN: A 240 PATIENT RANDOMIZED PLACEBO CONTROLLED TRIAL
    Tincello, Douglas
    Slack, Mark
    Kenyon, Sara
    Mayne, Christopher
    Toozs-Hobson, Philip
    Abrams, Keith
    Taylor, David
    NEUROUROLOGY AND URODYNAMICS, 2011, 30 (02) : 212 - 212
  • [28] Botulinum toxin treatment of temporomandibular joint pain in patients with bruxism: A prospective and randomized clinical study
    Kaya, D., I
    Ataoglu, H.
    NIGERIAN JOURNAL OF CLINICAL PRACTICE, 2021, 24 (03) : 412 - 417
  • [29] EFFICACY AND SAFETY OF BOTULINUM TOXIN A IN CHRONIC VULVAR PAIN - A RANDOMIZED CONTROLLED TRIAL
    Yoon, Hana
    JOURNAL OF SEXUAL MEDICINE, 2014, 11 : 218 - 218
  • [30] Evaluation of the effects of occlusal splint and masseter muscle injection in patients with myofascial pain: a randomised controlled trial
    Saglam, Reyhan
    Delilbasi, Cagri
    Ozel, Gulsum Sayin
    Subasi, Irmak Durur
    JOURNAL OF ORAL & FACIAL PAIN AND HEADACHE, 2024, 38 (03) : 64 - 76